Euflexxa
EUFLEXXA is supplied in 2.25 mL nominal volume, disposable, pre-filled glass syringes containing 2 mL of EUFLEXXA. Only the contents of the syringe are sterile. EUFLEXXA is nonpyrogenic. This product is not made with natural rubber latex. Product Number: 55566-4100-1. Three disposable syringes per carton.
Ferring Pharmaceuticals
Ferring Pharmaceuticals
As a privately-owned, biopharma company, Ferring focuses on developing life-changing innovations that help people live better lives. Grounded in a 70-year commitment to science and research, we are relentless in our pursuit of therapies that help people build families, stay healthy, and fight disease. Ferring is involved in areas such as reproductive medicine and maternal health, as well as specialty areas within gastroenterology and orthopedics
Hyaluronic acid created in a controlled environment with a precise, multi-step cleansing and filtering process. Animal free.
Euflexxa Joint Venture program is a hub that streamlines everything from coverage verification to patient support.
EUFLEXXA® (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).
- Do not use EUFLEXXA to treat patients who have a known hypersensitivity to hyaluronan preparations.
- Do not use EUFLEXXA to treat patients with knee joint infections, infections or skin disease in the area of the injection site.
- Mixing of quaternary ammonium salts such as benzalkonium chloride with hyaluronan solutions results in formation of a precipitate. EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use disinfectants for skin preparation that contain quaternary ammonium salts.
- Do not inject intravascularly because intravascular injection may cause systemic adverse events.
- Patients having repeated exposure to EUFLEXXA have the potential for an immune response; however, this has not been assessed in humans.
- Safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee has not been established.
- Remove any joint effusion before injecting.
- Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
- Do not use after expiration date.
- Protect from light.
- Do not re-use—dispose of the syringe after use.
- Do not use if the blister package is opened or damaged.
Adverse event information regarding the use of EUFLEXXA as a treatment for pain in OA of the knee was available from two sources; a 12-week multicenter clinical trial conducted in Germany, and a 26-week multicenter clinical trial conducted in the US.
The most common adverse events related to EUFLEXXA injections reported in the clinical studies are the following:
- Arthralgia
- Back pain
- Pain in extremity
- Musculoskeletal pain
- Joint swelling
The following adverse events are among those that may occur in association with intra-articular injections:
- Arthralgia
- Joint swelling
- Joint effusion
- Injection site pain
- Arthritis
Do not use EUFLEXXA if the package is open or damaged. Store in the original package at 2º–25ºC (36º–77ºF). Protect from light. Do not freeze.
